REQUEST A DEMO
Total
USD $0.00
Search more companies

Pfizer Srb D.O.O. (Serbia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Pfizer Srb D.O.O. Profile Updated: October 16, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English Download a sample report

Yusafarm was established in 1990 as a 50:50 joint-venture between local Inex-Hemofarm and US-based Pharmacia & UpJohn Co. The Serbian company is mainly engaged in wholesaling pharmaceutical products.

Headquarters
Tresnjinog Cveta 1
Belgrade; Belgrade; Postal Code: www.pfizer.co.rs

Contact Details: Purchase the Pfizer Srb D.O.O. report to view the information.

Website: http://CUBE_PROFILES_YU

Basic Information
Total Employees:
Purchase the Pfizer Srb D.O.O. report to view the information.
Outstanding Shares:
Purchase the Pfizer Srb D.O.O. report to view the information.
Registered Capital:
Purchase the Pfizer Srb D.O.O. report to view the information.
Incorporation Date:
January 17, 1990
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Representative
Ownership Details
Purchase this report to view the information.
50%
Purchase this report to view the information.
50%
Company Performance
Financial values in the chart are available after Pfizer Srb D.O.O. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency RSD. Absolute financial data is included in the purchased report.
Net sales revenue
-6.51%
Total operating revenue
-6.51%
Operating profit (EBIT)
-44.2%
EBITDA
-34.68%
Net Profit (Loss) for the Period
-58.23%
Total assets
7.6%
Total equity
5.1%
Operating Profit Margin (ROS)
-1.25%
Net Profit Margin
-1.43%
Return on Equity (ROE)
-7.36%
Debt to Equity Ratio
-1.37%
Quick Ratio
-0.11%
Cash Ratio
0.21%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?